Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection

Jordan J. Feld, Jason Grebely, Gail V. Matthews, Tanya Applegate, Margaret Hellard, Alana Sherker, Vera Cherepanov, Kathy Petoumenos, Barbara Yeung, John M. Kaldor, Andrew R. Lloyd, Gregory J. Dore

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Background: High plasma levels of interferon-gamma inducible protein-10 (IP-10) have been shown to be associated with impaired treatment response in chronic hepatitis C virus (HCV) infection. Whether IP-10 levels predict treatment in acute HCV infection is unknown. Methods: Patients with acute or early chronic HCV infection from the Australian Trial in Acute Hepatitis C (ATAHC) cohort were evaluated. Baseline and on-treatment plasma IP-10 levels were measured by ELISA. IL28B genotype was determined by sequencing. Results: Overall, 74 HCV mono-infected and 35 HIV/HCV co-infected patients were treated in ATAHC, of whom 89 were adherent to therapy and were included for analysis. IP-10 levels correlated with HCV RNA levels at baseline (r = 0.48, P<0.001) and during treatment. Baseline IP-10 levels were higher in patients who failed to achieve rapid virological response (RVR). Only one patient with a plasma IP-10 level >600 pg/mL achieved RVR. There was no association with IP-10 levels and early virological response (EVR) or sustained virological response (SVR). Conclusions: Baseline IP-10 levels are associated with early viral kinetics but not ultimate treatment outcome in acute HCV infection. Given previous data showing that patients with high baseline IP-10 are unlikely to spontaneously clear acute HCV infection, they should be prioritized for early antiviral therapy.

Original languageEnglish
Article numbere80003
Number of pages11
JournalPLoS ONE
Issue number11
Publication statusPublished - 20 Nov 2013
Externally publishedYes


  • Hepatitis C virus
  • interferons
  • gene expression
  • co-infections
  • HIV clinical manifestations
  • immune response
  • RNA sequencing
  • antiviral therapy

Cite this